<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705822</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976J_3502</org_study_id>
    <secondary_id>EudraCT #: 2004-003885-14</secondary_id>
    <nct_id>NCT00705822</nct_id>
  </id_info>
  <brief_title>Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer</brief_title>
  <acronym>PROSTATA</acronym>
  <official_title>Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer Who Have Relapse in Biochemistry Whilst Androgenic Blockage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To compare the efficacy of both strategies (reference treatment: Docetaxel+Prednisone and
      experimental treatment: Docetaxel+Estramustine+Hydrocortisone) by means of PSA values.

      To determine the time to treatment failure in both strategies To determine the overall and
      specific cause survival To evaluate the safety profile To analyze the Quality of Life
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment rate
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate over 50% in PSA</measure>
    <time_frame>every 3 weeks up to end of treatment and every month until PSA progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>from Informed Consent signature up to end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>from Informed Consent signature up to study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and specific cause surveillance</measure>
    <time_frame>from Informed Consent signature up to study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>from Informed Consent signature up to study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' Quality of Life</measure>
    <time_frame>Before first cycle, every 2 cycles throughout the treatment period, at the study end and first follow-up visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel + Estramustine + Hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel + Prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel + Estramustine + Hydrocortisone</intervention_name>
    <description>Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.
Combination of these 3 drugs every 3 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel + Prednisone</intervention_name>
    <description>Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological confirmation of prostate adenocarcinoma

          -  Advanced prostate carcinoma.

          -  Previous treatment with hormones

          -  Levels of testosterone &lt; 50 ng/dL

          -  Good hematological, liver and kidney function

          -  Previous treatment with surgery or radiotherapy, at least 4 weeks since end of
             treatment is allowed (the patient should have been recovered from any side effects.

        Exclusion Criteria:

          -  Previous chemotherapy (estramustine included).

          -  Second line hormonotherapy (oestrogens, gestagens, ketoconazole, ...included)

          -  Previous treatment with radiotherapy (isotopes) or previous radiotherapy over &gt; 25% of
             the marrow

          -  Any malignant process with a free disease interval under 5 years, exception done to
             non-melanoma skin cancer.

          -  Concomitant serious diseases

          -  Concomitant treatment with any other neoplassic therapy (exception done to LHRH
             agonists and/or biphosphonates).

          -  Contraindication for the treatment with estramustine.

          -  Previous history of pulmonary embolism, thromboembolic disease, previous treatment
             with anticoagulants (except aspirin), active thrombophlebitis or hypercoagulation.

          -  Previous history of pulmonary spillage or ascitis.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jos√© Taboada</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2008</study_first_posted>
  <last_update_submitted>November 29, 2010</last_update_submitted>
  <last_update_submitted_qc>November 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Estramustine</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

